BMRN

Biomarin Pharmaceutical Inc

Healthcare


Presented:06/06/2018
Price:$91.01
Cap:$16.03B
Current Price:$70.46
Cap:$13.41B

Presented

Date06/06/2018
Price$91.01
Market Cap$16.03B
Ent Value$14.08B
P/E RatioN/A
Book Value$15.89
Div Yield0%
Shares O/S176.15M
Ave Daily Vol1,321,751
Short Int5.90%

Current

Price$70.46
Market Cap$13.41B
BioMarin Pharmaceutical, Inc. is a biotechnology company, which develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its products include BioMarin, Brineura, Firdapse, Kuvan, Naglazyme, and Vimizim. The company was founded by Christopher M. Starr and Grant W. Denison on March 21, 1997 and is headquartered in San Rafael, CA.

Publicly traded companies mentioned herein: BioMarin Pharmaceutical Inc (BMRN), Pfizer Inc (PFE), Sangamo Therapeutics Inc (SGMO), Spark Therapeutics Inc (ONCE), UniQure Inc (QURE)

Highlights

BioMarin (BMRN) stock is flat YTD at ~$91, but shares have recently recovered some lost ground following concerns about valrox’s (valoctocogene roxaparvovec/BMN 270) durability. The presenter is long, and thinks the hemophilia A gene therapy has the potential to materially alter the ability to treat hemophilia A; however, the market is not giving the company credit for valrox’s potential. Further, the existing business could generate $2/share, or slightly better, of earnings looking out to 2020, and while this alone is not substantial, there’s another $2/share of R&D cost and multiple pipeline products that could provide optionality for a buyer of the business.

  • Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

  • Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Request access to DeMatteo Research for full access

Request Access

Already have an account?

Idea Discussion

Commentor 1 - 2 weeks ago

Signing up and creating account with us, unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Commentor 1 - 2 weeks ago

Signing up and creating account with us, unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Idea Discussions display submitted commentary from our investor community.

To read and participate in the discussion with the presenter and investor base, request access to DeMatteo

Request Access

Already have an account?

An error occurred loading this content. Try again later or contact us.